Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Liver Neoplasms"" wg kryterium: Temat


Tytuł:
Integrating Network Pharmacology and Experimental Validation to Decipher the Mechanism of Action of Astragalus - Atractylodes Herb Pair in Treating Hepatocellular Carcinoma.
Autorzy:
Liang Y; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Xie Y; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Liu X; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Yu L; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Yan H; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Shang Z; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Wu Y; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Cai X; Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China.
Shi W; Beijing University of Chinese Medicine, Beijing, 100029, People's Republic of China.
Du J; Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Yang Z; Center of Integrative Medicine, Beijing Ditan Hospital, Capital Medical University, Beijing, 100015, People's Republic of China.
Pokaż więcej
Źródło:
Drug design, development and therapy [Drug Des Devel Ther] 2024 Jun 11; Vol. 18, pp. 2169-2187. Date of Electronic Publication: 2024 Jun 11 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Liver Neoplasms*/metabolism
Drugs, Chinese Herbal*/pharmacology
Drugs, Chinese Herbal*/chemistry
Network Pharmacology*
STAT3 Transcription Factor*/metabolism
STAT3 Transcription Factor*/antagonists & inhibitors
Atractylodes*/chemistry
Antineoplastic Agents, Phytogenic*/pharmacology
Antineoplastic Agents, Phytogenic*/chemistry
Antineoplastic Agents, Phytogenic*/isolation & purification
Animals ; Humans ; Mice ; Molecular Docking Simulation ; Astragalus Plant/chemistry ; Cell Proliferation/drug effects ; Liver Neoplasms, Experimental/drug therapy ; Liver Neoplasms, Experimental/pathology ; Liver Neoplasms, Experimental/metabolism ; Interleukin-6/metabolism ; Interleukin-6/antagonists & inhibitors ; Medicine, Chinese Traditional ; Drug Screening Assays, Antitumor
Czasopismo naukowe
Tytuł:
Gypenoside L inhibits hepatocellular carcinoma by targeting the SREBP2-HMGCS1 axis and enhancing immune response.
Autorzy:
Xiao MY; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing 100081, China; School of Pharmacy, Minzu University of China, Beijing 100081, China.
Pei WJ; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing 100081, China; School of Pharmacy, Minzu University of China, Beijing 100081, China.
Li S; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing 100081, China; School of Pharmacy, Minzu University of China, Beijing 100081, China.
Li FF; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing 100081, China; School of Pharmacy, Minzu University of China, Beijing 100081, China.
Xie P; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing 100081, China; School of Pharmacy, Minzu University of China, Beijing 100081, China.
Luo HT; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing 100081, China; School of Pharmacy, Minzu University of China, Beijing 100081, China.
Hyun Yoo H; Pharmacomicrobiomics Research Center, College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do 15588, Republic of Korea. Electronic address: .
Piao XL; Key Laboratory of Ethnomedicine (Minzu University of China), Ministry of Education, Beijing 100081, China; School of Pharmacy, Minzu University of China, Beijing 100081, China. Electronic address: .
Pokaż więcej
Źródło:
Bioorganic chemistry [Bioorg Chem] 2024 Sep; Vol. 150, pp. 107539. Date of Electronic Publication: 2024 Jun 08.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/metabolism
Gynostemma*/chemistry
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Liver Neoplasms*/metabolism
Sterol Regulatory Element Binding Protein 2*/metabolism
Sterol Regulatory Element Binding Protein 2*/antagonists & inhibitors
Cell Proliferation*/drug effects
Humans ; Animals ; Mice ; Dose-Response Relationship, Drug ; Molecular Structure ; Drug Screening Assays, Antitumor ; Apoptosis/drug effects ; Structure-Activity Relationship ; Antineoplastic Agents, Phytogenic/pharmacology ; Antineoplastic Agents, Phytogenic/chemistry ; Mice, Inbred BALB C ; Mice, Nude ; Liver Neoplasms, Experimental/drug therapy ; Liver Neoplasms, Experimental/pathology ; Liver Neoplasms, Experimental/metabolism ; Plant Extracts
Czasopismo naukowe
Tytuł:
Validation of Core Ingredients and Molecular Mechanism of Cinobufotalin Injection Against Liver Cancer.
Autorzy:
Chen S; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Li M; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Xue C; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Zhou X; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Wei J; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Zheng L; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Duan Y; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Deng H; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.
Tang F; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.
Xiong W; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Xiang B; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Zhou M; NHC Key Laboratory of Carcinogenesis, Hunan Key Laboratory of Oncotarget Gene, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, People's Republic of China.; Cancer Research Institute, Central South University, Changsha, 410078, People's Republic of China.; The Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Central South University, Changsha, 410078, People's Republic of China.
Pokaż więcej
Źródło:
Drug design, development and therapy [Drug Des Devel Ther] 2024 Apr 23; Vol. 18, pp. 1321-1338. Date of Electronic Publication: 2024 Apr 23 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Bufanolides*/pharmacology
Bufanolides*/chemistry
Bufanolides*/administration & dosage
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Liver Neoplasms*/metabolism
Cell Proliferation*/drug effects
Antineoplastic Agents*/pharmacology
Antineoplastic Agents*/chemistry
Humans ; Animals ; Mice ; Drug Screening Assays, Antitumor ; Liver Neoplasms, Experimental/drug therapy ; Liver Neoplasms, Experimental/pathology ; Liver Neoplasms, Experimental/metabolism ; Mice, Inbred BALB C ; Cell Cycle/drug effects ; Mice, Nude ; Dose-Response Relationship, Drug ; Neoplasms, Experimental/drug therapy ; Neoplasms, Experimental/pathology ; Neoplasms, Experimental/metabolism ; Tumor Cells, Cultured ; Structure-Activity Relationship ; Molecular Structure ; Injections
Czasopismo naukowe
Tytuł:
Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.
Autorzy:
Song BG; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Goh MJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Kang W; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sinn DH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Gwak GY; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi MS; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Lee JH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Paik YH; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Pokaż więcej
Źródło:
Gut and liver [Gut Liver] 2024 Jul 15; Vol. 18 (4), pp. 709-718. Date of Electronic Publication: 2024 Jun 27.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/mortality
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/mortality
Bevacizumab*/therapeutic use
Bevacizumab*/administration & dosage
Antibodies, Monoclonal, Humanized*/therapeutic use
Humans ; Male ; Female ; Retrospective Studies ; Middle Aged ; Aged ; Adult ; Progression-Free Survival ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Treatment Outcome ; Republic of Korea ; Neoplasm Staging ; Antineoplastic Agents, Immunological/therapeutic use
Czasopismo naukowe
Tytuł:
Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study.
Autorzy:
Jeong S; Department of Biomedical Informatics, Korea University College of Medicine, Seoul, Korea.; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Oh YH; Department of Family Medicine, College of Medicine, Chung-Ang University Gwangmyeong Hospital, Chung-Ang University College of Medicine, Gwangmyeong, Korea.
Ahn JC; Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Choi S; Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Park SJ; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Kim HJ; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.
Lee G; Department of Family Medicine, Life Clinic, Seoul, Korea.
Son JS; Department of Internal Medicine, Hanyang University Hospital, Seoul, Korea.
Jang H; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
Lee DH; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.
Sha M; Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Chen L; The International Cooperation Laboratory on Signal Transduction, Eastern Hepatobiliary Surgery Hospital, Shanghai, China.; National Center for Liver Cancer, Shanghai, China.
Kim W; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Korea.; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
Park SM; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea.; Department of Family Medicine, Life Clinic, Seoul, Korea.
Pokaż więcej
Źródło:
Clinical and molecular hepatology [Clin Mol Hepatol] 2024 Jul; Vol. 30 (3), pp. 487-499. Date of Electronic Publication: 2024 May 07.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/diagnosis
Carcinoma, Hepatocellular*/complications
Liver Neoplasms*/diagnosis
Liver Neoplasms*/pathology
Liver Neoplasms*/complications
Humans ; Male ; Female ; Middle Aged ; Risk Factors ; Republic of Korea/epidemiology ; Adult ; Incidence ; Proportional Hazards Models ; Fatty Liver/complications ; Fatty Liver/diagnosis ; Aged ; Cohort Studies
Czasopismo naukowe
Tytuł:
Surgical margin status outcome of intraoperative indocyanine green fluorescence-guided laparoscopic hepatectomy in liver malignancy: a systematic review and meta-analysis.
Autorzy:
Tangsirapat V; Department of Surgery, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, 11120, Thailand.
Kengsakul M; Department of Obstetrics and Gynecology, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, 11120, Thailand.
Udomkarnjananun S; Division of Nephrology, Department of Medicine, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, 10330, Thailand.
Sookpotarom P; Department of Surgery, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, 11120, Thailand.
Rattanasakalwong M; Department of Surgery, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, 11120, Thailand.
Nuchanatanon J; Department of Surgery, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, 11120, Thailand.
Kongon P; Department of Surgery, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, 11120, Thailand.
Wongta K; Department of Surgery, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, 11120, Thailand. .; Department of Surgery, Panyananthaphikkhu Chonprathan Medical Center, 222 Tiwanon Road, Pak Kret, Nonthaburi, 11120, Thailand. .
Pokaż więcej
Źródło:
BMC surgery [BMC Surg] 2024 Jun 12; Vol. 24 (1), pp. 181. Date of Electronic Publication: 2024 Jun 12.
Typ publikacji:
Journal Article; Systematic Review; Meta-Analysis
MeSH Terms:
Indocyanine Green*
Hepatectomy*/methods
Liver Neoplasms*/surgery
Liver Neoplasms*/pathology
Laparoscopy*/methods
Margins of Excision*
Humans ; Surgery, Computer-Assisted/methods ; Optical Imaging/methods
Czasopismo naukowe
Tytuł:
Development of a Novel Comprehensive Hepatocellular Carcinoma Outcome Prognostic Scoring System With Integration of Imaging Features.
Autorzy:
Tran Cao HS; Department of Surgical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Witt RG; Department of Surgical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.; Department of Surgery, University of Virginia, Charlottesville, VA, USA.
Elsayes KM; Department of Abdominal Imaging, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Baiomy AA; Department of Interventional Radiology, Texas Tech University Health Sciences Center, El Paso, TX, USA.
Xiao L; Department of Biostatistics, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Palmquist S; Department of Abdominal Imaging, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Lee SS; Department of GI Medical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Mohamed YI; Department of GI Medical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Mahvash A; Department of Interventional Radiology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Tzeng CD; Department of Surgical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Chun YS; Department of Surgical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Koay EJ; Department of Radiation Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Rashid A; Department of Pathology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Hassan MM; Department of Epidemiology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Yao JC; Department of GI Medical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Vauthey JN; Department of Surgical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Kaseb AO; Department of GI Medical Oncology, U.T. MD Anderson Cancer Center, Houston, TX, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2024 Jun 03; Vol. 29 (6), pp. e803-e810.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/diagnostic imaging
Carcinoma, Hepatocellular*/mortality
Liver Neoplasms*/diagnostic imaging
Liver Neoplasms*/pathology
Liver Neoplasms*/mortality
Humans ; Male ; Female ; Prognosis ; Middle Aged ; Aged ; Magnetic Resonance Imaging/methods ; Tomography, X-Ray Computed/methods ; Adult ; Proportional Hazards Models ; Prospective Studies
Czasopismo naukowe
Tytuł:
Association between blood lipid levels and the risk of liver cancer: a systematic review and meta-analysis.
Autorzy:
Zhang Z; School of Nursing, Southwest Medical University, Luzhou, 646000, China.; Department of Gastrointestinal surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Xu S; School of Nursing, Southwest Medical University, Luzhou, 646000, China.; Department of Gastrointestinal surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Song M; School of Nursing, Southwest Medical University, Luzhou, 646000, China.
Huang W; School of Nursing, Southwest Medical University, Luzhou, 646000, China.; Department of Gastrointestinal surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Yan M; School of Nursing, Southwest Medical University, Luzhou, 646000, China.; Department of Gastrointestinal surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China.
Li X; Department of Gastrointestinal surgery, The Affiliated Hospital, Southwest Medical University, Luzhou, 646000, China. .
Pokaż więcej
Źródło:
Cancer causes & control : CCC [Cancer Causes Control] 2024 Jun; Vol. 35 (6), pp. 943-953. Date of Electronic Publication: 2024 Feb 20.
Typ publikacji:
Systematic Review; Journal Article; Meta-Analysis
MeSH Terms:
Liver Neoplasms*/blood
Liver Neoplasms*/epidemiology
Lipids*/blood
Humans ; Risk Factors
Czasopismo naukowe
Tytuł:
Liver cancer in China: the analysis of mortality and burden of disease trends from 2008 to 2021.
Autorzy:
Qin Y; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Tang C; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Li J; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China.
Gong J; Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, People's Republic of China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2024 May 16; Vol. 24 (1), pp. 594. Date of Electronic Publication: 2024 May 16.
Typ publikacji:
Journal Article
MeSH Terms:
Liver Neoplasms*/mortality
Liver Neoplasms*/epidemiology
Humans ; China/epidemiology ; Male ; Female ; Middle Aged ; Aged ; Adult ; Cost of Illness ; Aged, 80 and over ; Mortality/trends ; Young Adult ; Adolescent ; Rural Population/statistics & numerical data ; Infant ; Child, Preschool ; Urban Population/statistics & numerical data ; Child
Czasopismo naukowe
Tytuł:
Dichotomous roles of ADAR1 in liver hepatocellular carcinoma and kidney renal cell carcinoma: Unraveling the complex tumor microenvironment and prognostic significance.
Autorzy:
Mao JX; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Li JJ; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Lu XY; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Zhong HX; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Zhao YY; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Zhu LY; Department of Immunology and Medical Immunology State Key Laboratory, Naval Medical University, Shanghai 200433, China.
Fu H; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Ding GS; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China.
Teng F; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China. Electronic address: .
Chen M; Department of Urology, Changzheng Hospital, Naval Medical University, Shanghai 200003, China. Electronic address: .
Guo WY; Department of Liver Surgery and Organ Transplantation, Changzheng Hospital, Naval Medical University, Shanghai 200003, China. Electronic address: .
Pokaż więcej
Źródło:
International immunopharmacology [Int Immunopharmacol] 2024 Jul 30; Vol. 136, pp. 112340. Date of Electronic Publication: 2024 May 30.
Typ publikacji:
Journal Article
MeSH Terms:
Adenosine Deaminase*/genetics
Adenosine Deaminase*/metabolism
Tumor Microenvironment*
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
Liver Neoplasms*/metabolism
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/metabolism
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/mortality
Kidney Neoplasms*/genetics
Kidney Neoplasms*/pathology
Kidney Neoplasms*/metabolism
Kidney Neoplasms*/mortality
Carcinoma, Renal Cell*/genetics
Carcinoma, Renal Cell*/metabolism
Carcinoma, Renal Cell*/pathology
RNA-Binding Proteins*/metabolism
RNA-Binding Proteins*/genetics
Gene Expression Regulation, Neoplastic*
Humans ; Prognosis ; Female ; Male ; Biomarkers, Tumor/metabolism ; Biomarkers, Tumor/genetics ; Middle Aged
Czasopismo naukowe
Tytuł:
Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1α mRNA stability.
Autorzy:
Qiu J; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Zhong F; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Zhang Z; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Pan B; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Ye D; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Zhang X; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Yao Y; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Luo Y; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China.
Wang X; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China; Cancer Center of Fujian Medical University, Fujian Medical University Union Hospital, Fuzhou, China.
Tang N; Department of Hepatobiliary Surgery and Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou, China; Cancer Center of Fujian Medical University, Fujian Medical University Union Hospital, Fuzhou, China; Key Laboratory of Ministry of Education for Gastrointestinal Cancer, Fujian Medical University, Fuzhou, China; Key Laboratory of Clinical Laboratory Technology for Precision Medicine (Fujian Medical University), Fujian Province University, Fuzhou, China. Electronic address: .
Pokaż więcej
Źródło:
International immunopharmacology [Int Immunopharmacol] 2024 Jul 30; Vol. 136, pp. 112415. Date of Electronic Publication: 2024 Jun 07.
Typ publikacji:
Journal Article
MeSH Terms:
B7-H1 Antigen*/metabolism
B7-H1 Antigen*/genetics
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/immunology
Carcinoma, Hepatocellular*/metabolism
Gene Expression Regulation, Neoplastic*
Hypoxia-Inducible Factor 1, alpha Subunit*/metabolism
Hypoxia-Inducible Factor 1, alpha Subunit*/genetics
Liver Neoplasms*/genetics
Liver Neoplasms*/immunology
Liver Neoplasms*/metabolism
RNA Stability*
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
Animals ; Female ; Humans ; Male ; Mice ; Cell Hypoxia ; Cell Line, Tumor ; Mice, Inbred BALB C ; Mice, Nude ; MicroRNAs/genetics ; MicroRNAs/metabolism ; Tumor Escape/genetics ; Tumor Microenvironment/immunology
Czasopismo naukowe
Tytuł:
SLC25A19 is a novel prognostic biomarker related to immune invasion and ferroptosis in HCC.
Autorzy:
Liu S; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China.
Zhang P; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China.
Wu Y; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China.
Zhou H; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China.
Wu H; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China.
Jin Y; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China.
Wu D; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China.
Wu G; Hepatobiliary Surgery Department, First Hospital of China Medical, University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning, Province, PR China; Key Laboratory of General Surgery of Liaoning Province, the First Affiliated Hospital of China Medical University, No.155, Nanjingbei Street, 110001 Shenyang, Liaoning Province, PR China. Electronic address: .
Pokaż więcej
Źródło:
International immunopharmacology [Int Immunopharmacol] 2024 Jul 30; Vol. 136, pp. 112367. Date of Electronic Publication: 2024 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Ferroptosis*/genetics
Liver Neoplasms*/immunology
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
Liver Neoplasms*/mortality
Carcinoma, Hepatocellular*/immunology
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/mortality
Biomarkers, Tumor*/genetics
Biomarkers, Tumor*/metabolism
Humans ; Prognosis ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Female ; Male ; Middle Aged ; Cell Movement ; Cell Proliferation
Czasopismo naukowe
Tytuł:
Exosomal transfer of HCC-derived miR-17-5p downregulates NK cell function by targeting RUNX1-NKG2D axis.
Autorzy:
Zhou Z; Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China; School of Basic Medical Sciences, Fujian Medical University, Fuzhu, Fujian, China.
Li T; Department of Integrated Traditional and Western Medicine, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
Li J; Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China; School of Basic Medical Sciences, Fujian Medical University, Fuzhu, Fujian, China.
Lin W; Laboratory of Immuno-Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China; School of Basic Medical Sciences, Fujian Medical University, Fuzhu, Fujian, China. Electronic address: .
Zheng Q; Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China. Electronic address: .
Pokaż więcej
Źródło:
International immunopharmacology [Int Immunopharmacol] 2024 Jul 30; Vol. 136, pp. 112361. Date of Electronic Publication: 2024 May 30.
Typ publikacji:
Journal Article
MeSH Terms:
MicroRNAs*/genetics
MicroRNAs*/metabolism
Exosomes*/metabolism
Core Binding Factor Alpha 2 Subunit*/genetics
Core Binding Factor Alpha 2 Subunit*/metabolism
Carcinoma, Hepatocellular*/immunology
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/pathology
Killer Cells, Natural*/immunology
Killer Cells, Natural*/metabolism
Liver Neoplasms*/immunology
Liver Neoplasms*/genetics
Liver Neoplasms*/pathology
NK Cell Lectin-Like Receptor Subfamily K*/metabolism
NK Cell Lectin-Like Receptor Subfamily K*/genetics
Gene Expression Regulation, Neoplastic*
Humans ; Animals ; Cell Line, Tumor ; Zebrafish ; Down-Regulation ; Cytotoxicity, Immunologic
Czasopismo naukowe
Tytuł:
RNA-binding protein QKI promotes the progression of HCC by interacting with long non-coding RNA EGOT.
Autorzy:
Lu Y; Central Laboratory, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China.
Yang Z; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266071, China.
Zhang J; Central Laboratory, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China.
Ma X; Central Laboratory, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China.
Bi X; Central Laboratory, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China.
Xu L; Central Laboratory, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China.
Feng K; Central Laboratory, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China.
Wu Z; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266071, China.
Ma X; Department of Hepatobiliary and Pancreatic Surgery, The Affiliated Hospital of Qingdao University, Qingdao 266071, China. Electronic address: .
Zhuang L; Central Laboratory, Qingdao Municipal Hospital, Qingdao University, Qingdao 266071, China. Electronic address: .
Pokaż więcej
Źródło:
International immunopharmacology [Int Immunopharmacol] 2024 Jul 30; Vol. 136, pp. 112297. Date of Electronic Publication: 2024 May 29.
Typ publikacji:
Journal Article
MeSH Terms:
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/metabolism
Liver Neoplasms*/genetics
Liver Neoplasms*/metabolism
Liver Neoplasms*/pathology
RNA, Long Noncoding*/genetics
RNA, Long Noncoding*/metabolism
RNA-Binding Proteins*/metabolism
RNA-Binding Proteins*/genetics
Cell Proliferation*
Cell Movement*
Gene Expression Regulation, Neoplastic*
Humans ; Animals ; Cell Line, Tumor ; Mice ; Mice, Nude ; Male ; Disease Progression ; Female ; Mice, Inbred BALB C ; Middle Aged
Czasopismo naukowe
Tytuł:
CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.
Autorzy:
Liu Y; Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Engineering Research Center of Transplantation and Immunology, Shanghai, China; Shanghai Institute of Transplantation, Shanghai, China. Electronic address: .
Wang F; State Key Laboratory of Systems Medicine for Cancer, Renji-Med-X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yan G; Institute of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China.
Tong Y; State Key Laboratory of Systems Medicine for Cancer, Renji-Med-X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Guo W; State Key Laboratory of Systems Medicine for Cancer, Renji-Med-X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li S; School of Biomedical Engineering & Med-X Research Institute, Shanghai Jiao Tong University, Shanghai, China.
Qian Y; State Key Laboratory of Systems Medicine for Cancer, Renji-Med-X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Li Q; Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Shu Y; State Key Laboratory of Systems Medicine for Cancer, Renji-Med-X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang L; Institute of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: .
Zhang Y; Central Laboratory, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai, China. Electronic address: .
Xia Q; Department of Liver Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; Shanghai Engineering Research Center of Transplantation and Immunology, Shanghai, China; Shanghai Institute of Transplantation, Shanghai, China. Electronic address: .
Pokaż więcej
Źródło:
Cancer letters [Cancer Lett] 2024 Jul 28; Vol. 595, pp. 217006. Date of Electronic Publication: 2024 May 31.
Typ publikacji:
Journal Article
MeSH Terms:
Carnitine O-Palmitoyltransferase*/genetics
Carnitine O-Palmitoyltransferase*/metabolism
Carnitine O-Palmitoyltransferase*/antagonists & inhibitors
Tumor Suppressor Protein p53*/genetics
Tumor Suppressor Protein p53*/metabolism
Liver Neoplasms*/genetics
Liver Neoplasms*/drug therapy
Liver Neoplasms*/pathology
Liver Neoplasms*/metabolism
Carcinoma, Hepatocellular*/genetics
Carcinoma, Hepatocellular*/pathology
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/metabolism
Mutation*
Humans ; Animals ; Mice ; Amino Acids, Branched-Chain/metabolism ; Cell Line, Tumor ; TOR Serine-Threonine Kinases/metabolism ; TOR Serine-Threonine Kinases/genetics ; Xenograft Model Antitumor Assays ; Lipid Metabolism/genetics ; Signal Transduction ; Acetyl Coenzyme A/metabolism ; Gene Expression Regulation, Neoplastic ; Male
Czasopismo naukowe
Tytuł:
Dual Enzyme-Locked Activation Reporter for Accurate Liver Cancer Surveillance.
Autorzy:
Chen YJ; Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.; Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, P. R. China.
Zhang H; Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.
Xiang FF; Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, P. R. China.
Chen SY; Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, P. R. China.
Wu M; Department of Radiology and Huaxi MR Research Center (HMRRC), Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.
Li K; Key Laboratory of Green Chemistry and Technology of Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, P. R. China.
Pokaż więcej
Źródło:
Analytical chemistry [Anal Chem] 2024 Jul 23; Vol. 96 (29), pp. 12074-12083. Date of Electronic Publication: 2024 Jul 09.
Typ publikacji:
Journal Article
MeSH Terms:
Liver Neoplasms*/diagnosis
Liver Neoplasms*/metabolism
Leucyl Aminopeptidase*/metabolism
Leucyl Aminopeptidase*/analysis
Nitroreductases*/metabolism
Nitroreductases*/analysis
Humans ; Animals ; Carcinoma, Hepatocellular/diagnosis ; Carcinoma, Hepatocellular/metabolism ; Mice ; Fluorescent Dyes/chemistry ; Optical Imaging
Czasopismo naukowe
Tytuł:
Deciphering hepatoma cell resistance to tyrosine kinase inhibitors: insights from a Liver-on-a-Chip model unveiling tumor endothelial cell mechanisms.
Autorzy:
Poddar MS; Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu, 30044, Taiwan, Republic of China. .
Chu YD; Liver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China.; Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan, Republic of China.; Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China.
Yeh CT; Liver Research Center, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China.; Molecular Medicine Research Center, Chang Gung University, Taoyuan 333, Taiwan, Republic of China.; Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan 333, Taiwan, Republic of China.
Liu CH; Institute of Nanoengineering and Microsystems, National Tsing Hua University, Hsinchu, 30044, Taiwan, Republic of China. .; Department of Power Mechanical Engineering, National Tsing Hua University, Hsinchu 30044, Taiwan, Republic of China.; College of Semiconductor Research, National Tsing Hua University, Hsinchu 30044, Taiwan, Republic of China.
Pokaż więcej
Źródło:
Lab on a chip [Lab Chip] 2024 Jul 23; Vol. 24 (15), pp. 3668-3678. Date of Electronic Publication: 2024 Jul 23.
Typ publikacji:
Journal Article
MeSH Terms:
Liver Neoplasms*/drug therapy
Liver Neoplasms*/metabolism
Liver Neoplasms*/pathology
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/metabolism
Carcinoma, Hepatocellular*/pathology
Protein Kinase Inhibitors*/pharmacology
Lab-On-A-Chip Devices*
Drug Resistance, Neoplasm*/drug effects
Humans ; Endothelial Cells/drug effects ; Endothelial Cells/metabolism ; Endoglin/metabolism ; Endoglin/antagonists & inhibitors ; Neovascularization, Pathologic/drug therapy ; Neovascularization, Pathologic/metabolism ; Sorafenib/pharmacology ; Cell Line, Tumor ; Tyrosine Kinase Inhibitors ; Phenylurea Compounds ; Quinolines
Czasopismo naukowe
Tytuł:
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases.
Autorzy:
Ghosh CC; Trisalus Life Sciences, Westminster, Colorado, USA.
Cournoyer L; Department of Surgery, Brown University School of Medicine, Providence, RI, USA.
Liu Y; Trisalus Life Sciences, Westminster, Colorado, USA.
Ballarin A; Trisalus Life Sciences, Westminster, Colorado, USA.
Layman IB; Department of Surgery, Brown University School of Medicine, Providence, RI, USA.
LaPorte J; Trisalus Life Sciences, Westminster, Colorado, USA.
Morrissey M; Trisalus Life Sciences, Westminster, Colorado, USA.
Fraser K; Trisalus Life Sciences, Westminster, Colorado, USA.
Perati S; Trisalus Life Sciences, Westminster, Colorado, USA.
Cox BF; Trisalus Life Sciences, Westminster, Colorado, USA.
Yakirevich E; Department of Pathology, Brown University School of Medicine, Providence, Rhode Island, USA.
Treaba DO; Department of Pathology, Brown University School of Medicine, Providence, Rhode Island, USA.
Murtha TD; Department of Surgery, Brown University School of Medicine, Providence, RI, USA.
Guha P; Trisalus Life Sciences, Westminster, Colorado, USA.
Katz SC; Trisalus Life Sciences, Westminster, Colorado, USA.; Department of Surgery, Brown University School of Medicine, Providence, RI, USA.
Davar D; Department of Hematology and Oncology, UPMC Hillman Cancer Center, Pittsburgh, PA, USA .
Pokaż więcej
Źródło:
Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jul 22; Vol. 12 (7). Date of Electronic Publication: 2024 Jul 22.
Typ publikacji:
Journal Article
MeSH Terms:
Myeloid-Derived Suppressor Cells*/drug effects
Myeloid-Derived Suppressor Cells*/immunology
Myeloid-Derived Suppressor Cells*/metabolism
Liver Neoplasms*/drug therapy
Liver Neoplasms*/secondary
Immune Checkpoint Inhibitors*/pharmacology
Immune Checkpoint Inhibitors*/administration & dosage
Immune Checkpoint Inhibitors*/therapeutic use
Animals ; Mice ; Humans ; Drug Delivery Systems ; Mice, Inbred C57BL ; Cell Line, Tumor
Czasopismo naukowe
Tytuł:
Efficacy comparison of immune combination therapies in subgroups for advanced hepatocellular carcinoma patients: Systematic review and network meta-analysis.
Autorzy:
Wang Y; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
Lau W; Faculty of Medicine, Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Hong Kong, SAR, China.
Li Y; Department of Epidemiology, College of Preventive Medicine, Army Medical University (Third Military Medical University), Chongqing, China.
Tian Y; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
Lei Y; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
Xia F; Key Laboratory of Hepatobiliary and Pancreatic Surgery, Institute of Hepatobiliary Surgery, Southwest Hospital, the First Hospital Affiliated to AMU (Southwest Hospital), Chongqing, China.
Wang J; Key Laboratory of Biorheological Science and Technology, Ministry of Education, College of Bioengineering, Chongqing University, Chongqing, China.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2024 Jul 22; Vol. 19 (7), pp. e0306869. Date of Electronic Publication: 2024 Jul 22 (Print Publication: 2024).
Typ publikacji:
Journal Article; Systematic Review; Meta-Analysis; Comparative Study
MeSH Terms:
Carcinoma, Hepatocellular*/drug therapy
Carcinoma, Hepatocellular*/therapy
Carcinoma, Hepatocellular*/immunology
Carcinoma, Hepatocellular*/pathology
Liver Neoplasms*/drug therapy
Liver Neoplasms*/therapy
Liver Neoplasms*/immunology
Immunotherapy*/methods
Network Meta-Analysis*
Humans ; Sorafenib/therapeutic use ; Treatment Outcome ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Protein Kinase Inhibitors/therapeutic use
Czasopismo naukowe
Tytuł:
In utero exposure to antihistamines and risk of hepatocellular carcinoma in a multigenerational cohort.
Autorzy:
Murphy CC; Department of Health Promotion & Behavioral Sciences, University of Texas Health Science Center at Houston (UTHealth Houston), School of Public Health, Houston, Texas, USA.
Seif El Dahan K; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Singal AG; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.; Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, USA.
Cirillo PM; Child Health and Development Studies, Public Health Institute, Berkeley, California, USA.
Krigbaum NY; Child Health and Development Studies, Public Health Institute, Berkeley, California, USA.
Cohn BA; Child Health and Development Studies, Public Health Institute, Berkeley, California, USA.
Pokaż więcej
Źródło:
Hepatology communications [Hepatol Commun] 2024 Jul 22; Vol. 8 (8). Date of Electronic Publication: 2024 Jul 22 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Liver Neoplasms*/epidemiology
Liver Neoplasms*/chemically induced
Carcinoma, Hepatocellular*/epidemiology
Carcinoma, Hepatocellular*/chemically induced
Prenatal Exposure Delayed Effects*/chemically induced
Prenatal Exposure Delayed Effects*/epidemiology
Histamine Antagonists*/adverse effects
Histamine Antagonists*/therapeutic use
Humans ; Female ; Pregnancy ; Adult ; Male ; Risk Factors ; Cohort Studies ; Proportional Hazards Models ; Young Adult ; Adolescent
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies